Announcements Trials
Browse Landscape

Phase

Phase 1 17Phase 1/2 16Phase 2 5Phase 3 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, T-Cell, Peripheral 2

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 183Docetaxel 167Gemcitabine 165Oxaliplatin 162Carboplatin 161Paclitaxel 152Leucovorin 122Drug Therapy 119Dexamethasone 119Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 57Neoadjuvant Therapy 53Lenalidomide 52Letrozole 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × OTHER × romidepsin × Clear all
NCT01796002 2023-01-10

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

The Lymphoma Academic Research Organisation

Phase 3 Completed
421 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03355768 2018-12-19

Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Columbia University

Phase 3 Withdrawn
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡